Patents by Inventor Susan P. Perrine
Susan P. Perrine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9095565Abstract: Methods of treating blood disorders are described.Type: GrantFiled: June 20, 2014Date of Patent: August 4, 2015Assignee: Phoenicia Biosciences, Inc.Inventor: Susan P. Perrine
-
Publication number: 20140301975Abstract: Methods of treating blood disorders are described.Type: ApplicationFiled: June 20, 2014Publication date: October 9, 2014Inventor: Susan P. Perrine
-
Patent number: 8759378Abstract: Methods of treating blood disorders are described.Type: GrantFiled: September 17, 2008Date of Patent: June 24, 2014Assignee: Phoenicia Biosciences, Inc.Inventors: Susan P Perrine, Regine Bohacek
-
Patent number: 8618068Abstract: Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.Type: GrantFiled: December 8, 2010Date of Patent: December 31, 2013Assignees: Trustees of Boston University, Hemaquest Pharmaceuticals, Inc.Inventors: Susan P Perrine, Douglas V Faller, Ronald J Berenson
-
Patent number: 8242172Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: GrantFiled: July 14, 2010Date of Patent: August 14, 2012Assignee: Trustees of Boston UniversityInventor: Susan P. Perrine
-
Publication number: 20110251149Abstract: Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.Type: ApplicationFiled: December 8, 2010Publication date: October 13, 2011Applicants: Trustees of Boston University, HemaQuest Pharmaceuticals, Inc.Inventors: Susan P. Perrine, Douglas V. Faller, Ronald J. Berenson
-
Publication number: 20110086869Abstract: Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.Type: ApplicationFiled: September 24, 2010Publication date: April 14, 2011Applicant: THE TRUSTEES OF BOSTON UNIVERSITYInventors: SUSAN P. PERRINE, DOUGLAS V. FALLER
-
Patent number: 7910624Abstract: The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.Type: GrantFiled: June 6, 1995Date of Patent: March 22, 2011Assignee: The Trustees of Boston UniversityInventors: Susan P. Perrine, Douglas V. Faller
-
Publication number: 20100280113Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: ApplicationFiled: July 14, 2010Publication date: November 4, 2010Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Publication number: 20090137567Abstract: Methods of treating blood disorders are described.Type: ApplicationFiled: September 17, 2008Publication date: May 28, 2009Applicant: HEMAQUEST PHARMACEUTICALS, INC.Inventors: Susan P. Perrine, Regine Bojacek
-
Publication number: 20090082444Abstract: The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.Type: ApplicationFiled: August 28, 2008Publication date: March 26, 2009Applicant: THE TRUSTEES OF BOSTON UNIVERSITYInventors: Susan P. Perrine, Douglas V. Faller
-
Patent number: 7265153Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: GrantFiled: July 1, 2002Date of Patent: September 4, 2007Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Publication number: 20030018069Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: ApplicationFiled: July 1, 2002Publication date: January 23, 2003Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Patent number: 6451334Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia, blood loss, and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: GrantFiled: April 30, 2001Date of Patent: September 17, 2002Inventor: Susan P. Perrine
-
Patent number: 6403647Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. The, invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: GrantFiled: April 25, 2000Date of Patent: June 11, 2002Inventor: Susan P. Perrine
-
Publication number: 20010034367Abstract: The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.Type: ApplicationFiled: February 15, 2001Publication date: October 25, 2001Inventors: Douglas V. Faller, Susan P. Perrine, George Stamatoyannopoulos
-
Publication number: 20010027215Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia, blood loss, and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: ApplicationFiled: April 30, 2001Publication date: October 4, 2001Applicant: Susan PerrineInventor: Susan P. Perrine
-
Patent number: 6231880Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia, blood loss, and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: GrantFiled: May 29, 1998Date of Patent: May 15, 2001Inventor: Susan P. Perrine
-
Patent number: 6011000Abstract: The invention relates to compositions containing chemical compounds and compositions containing steel factor which stimulate the expression of hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia and other blood disorders. The invention also relates to methods for administering these compositions to patients and to medical aids for the treatment and prevention of blood and other disorders.Type: GrantFiled: June 6, 1995Date of Patent: January 4, 2000Inventors: Susan P. Perrine, Douglas V. Faller
-
Patent number: 5939456Abstract: The invention relates to novel compositions and to methods for the pulsed administration of compositions to a patient or to cells in vitro for the treatment of human blood disorders. Compositions contain chemical compounds that stimulate the expression of fetal hemoglobin and/or stimulate the proliferation of red blood cells, white blood cells and platelets in patients and ex vivo for reconstitution of hematopoiesis in vivo. These methods are useful to treat or prevent the symptoms associated with anemia, sickle cell disease, thalassemia and other blood disorders. The invention also relates to methods for the pulsed administration of compositions to patients for the treatment and prevention of cell proliferative disorders including deficiencies such as cytopenia and malignancies such as viral-induced tumors, other forms of neoplasia and for expansion of cells for hematopoietic transplantation. Pulsed administration has been shown to be more effective than continuous therapy in patients tested.Type: GrantFiled: July 26, 1996Date of Patent: August 17, 1999Inventor: Susan P. Perrine